Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving blood clotting factor
Reexamination Certificate
2011-05-03
2011-05-03
Weber, Jon P (Department: 1657)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving blood clotting factor
C435S007210, C435S287100, C514S013700, C514S014900
Reexamination Certificate
active
07935498
ABSTRACT:
Methods, compositions and kits are disclosed for identifying patients with an increased risk of experiencing an adverse cardiovascular event where the patient is undergoing aspirin antiplatelet therapy. A platelet-containing sample from the patient is evaluated for platelet hyperactivity and platelet hyperactivity in the sample is related to the patient's risk of an adverse cardiovascular event. In some embodiments the evaluation for platelet hyperactivity is carried out by assessing the function of platelets in the sample using a high shear platelet function test.
REFERENCES:
patent: 5256538 (1993-10-01), Aiken et al.
patent: 6124101 (2000-09-01), Coughlin
patent: 6210877 (2001-04-01), Francis et al.
patent: 6410337 (2002-06-01), Brady et al.
patent: 6780605 (2004-08-01), Frostegard
patent: 2003/0100036 (2003-05-01), Vojdani
patent: 2003/0109420 (2003-06-01), Valkirs et al.
patent: 2003/0124615 (2003-07-01), Ens
patent: 2004/0115735 (2004-06-01), Yusuf et al.
patent: 2004/0131500 (2004-07-01), Chow
patent: 2004/0185516 (2004-09-01), Frostegard
patent: 2005/0019742 (2005-01-01), Jennings et al.
patent: 2005/0181386 (2005-08-01), Diamond et al.
patent: 2005/0196748 (2005-09-01), Ericson
patent: 2005/0250156 (2005-11-01), Shebuski et al.
patent: 2005/0255534 (2005-11-01), Ericson
Frossard et al. “Platelet Function Predicts Myocardial Damage in Patients with Acute Myocardial Infarction”. Circulation (2004) 110: 1392-1397.
Wang et al. “Incidence of Aspirin Nonresponsiveness Using the Ultegra Rapid Platelet Function Assay-ASA”. Am J Cardiol. (2003) 92: 1492-1494.
Alberts et al. “Antiplatelet Effect of Aspirin in Patients with Cerebrovascular Disease”. Stroke (2004)35: 175-178.
Chen, W-H et al. “Aspirin Resistance is Associated with a High Incidence of Myonecrosis After Non-urgent Percutaneous Coronary Intervention Despite Clopidogrel Pretreatment”. J. Am. Coll. Cardoil. (2004)43: 1127-1129.
Macchi et al. “Resistance to Aspirin in Vitro is Associated with Increased Platelet Sensitivity to Adenosine Diphosphate”. Throm Res. (2002)107: 45-49.
Jilma, B. “Platelet Function Analyzer (PFA-100): A Tool to Quantify Congenital or Acquired Platelet Dysfunction”. J. Lab. Clin. Med. (2001)138: 152-163.
Gum et al. “A Prospective, Blinded Determination of the Natural History of Aspirin Resistance Among Stable Patients with Cardiovascular Disease”. J. Am Coll. Cardiol. (2003)41: 961-965.
Gum et al. “Profile and Prevalence of Aspirin Resistance in Patients with Cardiovascular Disease”. J. Am Coll. Cardiol. (2001) 88: 230-235.
Furman et al. “Increased Platelet Reactivity and Circulating Monocyte-platelet Aggregates in Patients with Stable Coronary Artery Disease”. J. Am Coll. Cardiol. (1998)31: 352-358.
Macchi et al. “Resistance in vitro to Low-dose Aspirin is Associated with Platelet P1A1 (GP IIIa) Polymorphism but not with 807T (GPla/Ila) and C-5T Kosak (GP Ibα) Polymorphisms”. J. Am Coll. Cardiol. (2003)42: 1115-1119.
Matetzky et al. “Clopidogrel Resistance is Associated with Increased Risk of Recurrent Atherothrombotic Events in Patients with Acute Myocardial Infarction”. Circulation (2004)109: 3171-3175.
Eikelboom et al. “Aspirin-resistant Thromboxane Biosynthesis and the Risk of Myocardial Infarction, Stroke or Cardiovascular Death in Patients at High Risk for Cardiovascular Events”. Circulation (2002)105: 1650-1655.
Grundmann et al: “Aspirin Non-responder status in patients with recurrent cerebral ischemic attacks.” Journal of Neurology, vol. 250, No. 1, Jan. 2003, pp. 63-66, XP002527965, ISSN: 0340-5354.
Frelinger et al: “Patients with coronary artery disease have an increased incidence of aspirin resistance: Association of PFA-100 closure time with clinical findings”, BLOOD, vol. 104, No. 11, Part 1, Nov. 2004. Page 514A, XP009116980 & 46th Annual Meeting of the American-Society-of-Hemotolgy; San Diego, CA; Dec. 4-7, 2004 ISSN: 0006-4971.
Gianetti, J. et al., “Platelet Activation Predicts Recurrent Ischemic Events After Percutaneous Coronary Angioplasty: A 6 Months Prospective Study”, Thrombosis Research, (2006), vol. 118, pp. 487-493.
Gough Tiffany M
Leitereg Theodore J.
Siemens Healthcare Diagnostics Inc.
Weber Jon P
LandOfFree
Methods for identifying patients with increased risk of an... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for identifying patients with increased risk of an..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for identifying patients with increased risk of an... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2692759